KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Capital Expenditures (2018 - 2025)

ClearPoint Neuro's Capital Expenditures history spans 12 years, with the latest figure at $199000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures rose 1558.33% year-over-year to $199000.0; the TTM value through Sep 2025 reached $474000.0, up 1336.36%, while the annual FY2024 figure was $275000.0, 61.65% down from the prior year.
  • Capital Expenditures for Q3 2025 was $199000.0 at ClearPoint Neuro, down from $263000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $323000.0 in Q2 2023 and bottomed at -$35000.0 in Q2 2021.
  • The 5-year median for Capital Expenditures is $69000.0 (2022), against an average of $107466.7.
  • The largest annual shift saw Capital Expenditures tumbled 94.89% in 2024 before it surged 1558.33% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $38000.0 in 2021, then rose by 2.63% to $39000.0 in 2022, then tumbled by 46.15% to $21000.0 in 2023, then soared by 1152.38% to $263000.0 in 2024, then dropped by 24.33% to $199000.0 in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Capital Expenditures are $199000.0 (Q3 2025), $263000.0 (Q4 2024), and $12000.0 (Q3 2024).